These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1452 related items for PubMed ID: 23696234
1. Cost effectiveness of biologic therapies for plaque psoriasis. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234 [Abstract] [Full Text] [Related]
2. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329 [Abstract] [Full Text] [Related]
3. Economic evaluation of systemic therapies for moderate to severe psoriasis. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346 [Abstract] [Full Text] [Related]
4. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421 [Abstract] [Full Text] [Related]
6. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663 [Abstract] [Full Text] [Related]
7. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Weinberg JM. Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953 [Abstract] [Full Text] [Related]
11. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R. Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890 [Abstract] [Full Text] [Related]
13. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424 [Abstract] [Full Text] [Related]
15. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. Ferrándiz C, García A, Blasco AJ, Lázaro P. J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264 [Abstract] [Full Text] [Related]
16. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T. Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658 [Abstract] [Full Text] [Related]
17. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. Wang SH, Chi CC, Hu S. Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910 [Abstract] [Full Text] [Related]